Mission Therapeutics

Mitochondria
#Mission Therapeutics #Neuroscience #Parkinson's #Phase I trial

Mission doses first Parkinson’s patient in Phase Ib study

Mission Therapeutics has dosed the first patient in its Phase Ib proof-of-mechanism study of MTX325 in patients with Parkinson’s disease (PD).  MTX325 is a first-in-class, highly potent and selective, orally bioavailable and brain-penetrant inhibitor of the deubiquitinating enzyme (DUB) USP30.   It has been designed to… Read More

#News

Parkinson's disease
#Financing #Mission Therapeutics #Parkinson's

Mission Therapeutics raises $13.3 million for Parkinson’s treatment

Biotech company Mission Therapeutics has raised $13.3 million to progress the clinical development of its lead candidate for the treatment of Parkinson’s disease.  The lead candidate MTX35 works by inhibiting USP30, a mitochondrial de-ubiquitylating enzyme (DUB), increasing mitochondrial ubiquitylation and promoting appropriate mitophagy. This is the essential process cells use… Read More

#Business & Investment #News

Neurons in a brain with Alzheimer's disease
#Drug discovery #Mission Therapeutics #Mitophagy #Neurodegenerative disorders #Neuroscience

Can neurodegenerative diseases be tackled by enhancing mitophagy?

Mission Therapeutics, a clinical-stage biotech company developing first-in-class therapeutics targeting mitophagy, has announced the publication of a review article titled ‘Targeting mitophagy in neurodegenerative diseases’ in the journal Nature Reviews Drug Discovery. The article outlines the progress scientists have made in identifying that mitochondrial dysfunction is… Read More

#News

#Funding #Mission Therapeutics #Neurodegenerative disorders #Parkinson's #The Michael J Fox Foundation for Parkinson’s Research (MJFF)

Mission awarded $5.2m for disease-modifying Parkinson’s treatment

Mission Therapeutics has been awarded $5.2 million from The Michael J. Fox Foundation for Parkinson’s Research (MJFF) and Parkinson’s UK. The funding will help advance Mission’s potential disease-modifying treatment for Parkinson’s disease (PD), MTX325. MTX325 is a potent, selective, small molecule brain-penetrant USP30 inhibitor, which is designed to protect dopamine-producing… Read More

#Business & Investment #Editor's Choice #News

Neuroscience Parkinson's disease
#Bayer #Biogen #BlueRock Therapeutics #Cell therapy #Ionis Pharmaceuticals #Mission Therapeutics #Neuroscience #Parkinson's #Small molecul #Stem cells #Vaxxinity #Vesper Bio

Exploring new frontiers in Parkinson’s Disease   

With debilitating symptoms including tremor, slow movement, rigidness and pain, Parkinson’s disease remains one of the most feared neurodegenerative conditions. DDW's Megan Thomas reports on the latest clinical progress as pharma and biotech search for new therapies for this currently incurable condition.  Parkinson’s is the most common movement disorder, affecting around… Read More

#Exclusive Content #Trends & Analysis

#Financing #Mission Therapeutics #Neurodegenerative disorders #Neuroscience #Parkinson's

£25.2 million raised to progress Parkinson’s treatment

Mission Therapeutics has raised £25.2 ($32.1) million to accelerate development of its lead drug candidates in the area of mitophagy, MTX325 and MTX652, through clinical trials. The financing was jointly led by existing investors Pfizer Venture Investments, Sofinnova Partners, Roche Venture Fund, SR One, IP Group, and Rosetta Capital. MTX325… Read More

#Business & Investment #News

Neurons
#Harvard Medical School #Mission Therapeutics #Neurodegenerative disorders #Neuroscience #Parkinson's #University of Cambridge

Potential disease-modifying therapy for Parkinson’s disease

An experimental drug has shown potential as a disease-modifying therapy for Parkinson’s disease, according to a new study published in Nature Communications. The peer-reviewed article titled ‘Knockout or inhibition of USP30 protects dopaminergic neurons in a Parkinson’s disease (PD) mouse model’ was the result of collaborative… Read More

#Editor's Choice #News